康龍化成(03759.HK)公開發售超購約114.23倍 預期11月28日上市
格隆匯11月27日丨康龍化成(03759.HK)公佈，發售1.17億股，其中香港發售5826.81萬股，國際發售5826.8萬股；發售價每股39.50港元；每手100股；預期11月28日上市。
公告顯示，公開發售獲大幅超額認購，相當於根據香港公開發售初步可供認購的香港發售股份總數約114.23倍。
國際發售獲大幅超額認購，分配給國際發售承配人的發售股份最終數目為5826.8萬股發售股份，佔超額配股權獲行使前根據全球發售初步可供認購發售股份總數約50%。
基石投資者方面，(i)中國國有企業結構調整基金股份有限公司；(ii) Lake Bleu Prime Healthcare Master Fund Limited；(iii) OrbiMed Partners Master Fund Limited；(iv) Worldwide Healthcare Trust PLC；(v) OrbiMed Global Healthcare Master Fund, L.P.；(vi) OrbiMed Genesis Master Fund, L.P.；(vii) Athos Asia Event Driven Master Fund；及(viii) Oaktree Capital Management, L.P.各自已分別認購793.16萬股發售股份、793.16萬股發售股份、162.2萬股發售股份、307.19萬股發售股份、85.82萬股發售股份、39.66萬股發售股份、495.72萬股發售股份及495.72萬股發售股份。
公告稱，所得款項淨額將約為43.44億港元。其中，約30%將用於擴展公司中國實驗室及生產設施的產能及能力；約10%用於撥付公司於美國及英國業務的進一步擴張；約20%用於建立公司有關研發生物製劑的醫藥研發服務平台；約15%將用於擴展公司的臨牀開發服務實力及能力；約15%用於透過潛在收購在美國、歐洲、日本或中國提供醫藥研發服務且擁有尖端研發技術的合同研發服務及合同生產服務公司業務，來擴展公司的產能；約10%用於公司的一般企業用途及用作營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
